The biochemical pharmacology of thromboxane synthase inhibition in man.
about
Failure of aspirin to prevent atherothrombosis: potential mechanisms and implications for clinical practice11-Hydroxythromboxane B2 dehydrogenase is identical to cytosolic aldehyde dehydrogenaseNew antithrombotic drugs for systemic and local delivery for coronary artery disease.Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.Understanding the role of prostaglandin E2 in regulating human platelet activity in health and diseaseRedirection of prostaglandin endoperoxide metabolism at the platelet-vascular interface in manSystemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptorThromboxane A2 receptor antagonists.Antiplatelet therapy: targeting the TxA2 pathway.Platelet and vessel associated prostacyclin and thromboxane A2/prostaglandin endoperoxide receptors.Metabolism of arachidonic acid.Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.New Antithrombotic Drugs of Coronary Artery Disease.Eicosanoids and hypertension.Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.Human thromboxane synthase: comparative modeling and docking evaluation with the competitive inhibitors Dazoxiben and Ozagrel.Effects of BM-573, a novel thromboxane A2 inhibitor, on pulmonary hemodynamics in endotoxic shock.Aspirin is insufficient in inhibition of platelet aggregation and thromboxane formation early after coronary artery bypass surgery.Thromboxanes: Synthase and receptorsSynthesis of Some Guanylhydrazones and Imidazolinylhydrazones as Thromboxane-Synthase and Platelet Aggregation Inhibitors
P2860
Q28167273-AB8BD990-706B-4A2D-A4AE-5927EA0FE2D2Q28623241-18742C70-B4AE-4BA2-B20C-05168B533997Q33568892-9C553061-18F0-4707-BC03-EA085AC63A75Q34285416-1098DC37-8827-4FEA-AB76-9EA89313D7B8Q34480894-39CF6078-E58A-4836-ACAC-38B8BFC5ADA4Q34565519-D037F5FD-D2CD-4DF7-9B42-A1AF4F3C640FQ34803113-1E3CA370-6A52-4669-A8AF-B3D852814579Q35593380-417DB4B3-DF35-447D-8201-BC0150454740Q35874422-A2BE9BDF-B1D7-4BA5-A1A0-F6B63EFE1E73Q37113049-61DFF3F0-C2C8-406C-A8AD-613F499265BEQ38172461-25561AE3-7149-4796-B2EC-96FD2FC372D4Q38187995-01066BAF-B543-4C50-851D-4B9DF5031DB8Q39603096-A7C1577B-FC6F-479A-8287-A065CE43473FQ41015991-5DC80D25-45D4-4B9F-82C0-A85926235557Q41720782-D5FDAFAC-2CFF-4AA5-B8FB-E343B0D9A946Q42541936-AF2FE9F3-5579-42BD-A88A-59B1731E42D1Q42560642-698BC2B7-2D6A-4B61-9877-91825EAA41CEQ44428752-C0283280-D507-4E62-A205-BA0511810350Q44769877-1062A808-10A7-4503-991D-A162F55E6690Q46617225-559EFD96-72B3-4517-872A-E62F1BDDD2E7Q55919722-296C4A9C-D634-4F88-B501-9B0ACBEC0C44Q58412049-1EA6FEFC-F443-41A8-886A-F1BC10A5E866
P2860
The biochemical pharmacology of thromboxane synthase inhibition in man.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh
1985年學術文章
@zh-hant
name
The biochemical pharmacology of thromboxane synthase inhibition in man.
@en
The biochemical pharmacology of thromboxane synthase inhibition in man.
@nl
type
label
The biochemical pharmacology of thromboxane synthase inhibition in man.
@en
The biochemical pharmacology of thromboxane synthase inhibition in man.
@nl
prefLabel
The biochemical pharmacology of thromboxane synthase inhibition in man.
@en
The biochemical pharmacology of thromboxane synthase inhibition in man.
@nl
P2093
P356
P1433
P1476
The biochemical pharmacology of thromboxane synthase inhibition in man.
@en
P2093
FitzGerald GA
Pedersen AK
P304
P356
10.1161/01.CIR.72.6.1194
P407
P577
1985-12-01T00:00:00Z